Pediatric Intracranial Hypertension: a Current Literature Review
Shawn C Aylward1, Amanda L Way2
1Department of Neurology, Nationwide Children's Hospital, The Ohio State University College of Medicine, 700 Children's Drive, Columbus, OH, 43205, USA. Shawn.Aylward@nationwidechildrens.org.
Insights
Pediatric intracranial hypertension affects children, with incidence rates around 0.7 per 100,000. Adult trial data suggests acetazolamide is a viable first-line treatment for this condition.
Area of Science:
- Pediatric Neurology
- Ophthalmology
- Clinical Trials
Background:
- Pediatric intracranial hypertension (PIH) is a serious condition impacting children's quality of life.
- Untreated PIH can lead to significant morbidity.
Purpose of the Study:
- To provide an updated review of pediatric intracranial hypertension.
- To summarize current understanding and treatment approaches for PIH.
Main Methods:
- Review of existing literature and clinical trial data.
- Analysis of findings from adult studies and their translation to pediatric care.
Main Results:
- Estimated pediatric incidence of PIH is 0.63-0.71 per 100,000 in the USA and Britain.
- Adult trials show acetazolamide improves visual fields, optical coherence tomography, Frisen grade, and quality of life.
- These adult findings are being applied to the pediatric population.
Conclusions:
- Acetazolamide is considered an acceptable first-line medication for PIH, based on adult data.
- Further pediatric-specific treatment studies are needed.
- Early diagnosis and treatment are crucial to prevent long-term complications.
Purpose Of Review:
The purpose of this review is to provide an update on pediatric intracranial hypertension.
Recent Findings:
The annual pediatric incidence is estimated at 0.63 per 100,000 in the USA and 0.71 per 100,000 in Britain. The Idiopathic Intracranial Hypertension Treatment Trial found improvement in visual fields, optical coherence tomography, Frisen grade, and quality of life with acetazolamide compared to placebo in adult patients, and these findings have been translated to the pediatric population. Pediatric intracranial hypertension is a disorder that if left untreated can lead to poor quality of life and morbidity. There are no current treatment studies in pediatrics, but adult data suggests acetazolamide remains an acceptable first-line medication.
More Related Videos
Related Concept Videos
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Hypertension I: Introduction
Hypertension II: Pathophysiology
Hypertension V: Nursing Management
Electrical Current


